Cargando…

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of on-line flow cytometry. Data of four previously untreated patients showed that cyclosporin-A can increase i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E., Planting, A. S., Seynaeve, C., Stoter, G., Nooter, K.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977533/ https://www.ncbi.nlm.nih.gov/pubmed/1892765

Ejemplares similares

Multidrug resistance (mdr) genes in human cancer.
por: Nooter, K., et al.
Publicado: (1991)

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
por: Planting, A. S., et al.
Publicado: (1993)

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.
por: Planting, A. S., et al.
Publicado: (1996)

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
por: van der Wall, E., et al.
Publicado: (1996)

A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
por: Pronzato, P., et al.
Publicado: (1996)

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
por: Ma, J., et al.
Publicado: (1995)

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.
por: Pronzato, P., et al.
Publicado: (1998)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
por: Punt, C. J., et al.
Publicado: (1997)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.
por: Nooter, K., et al.
Publicado: (1997)

Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.
por: Burger, H., et al.
Publicado: (1998)

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002)

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
por: Pyrhönen, S., et al.
Publicado: (1995)

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
por: de Jongh, F E, et al.
Publicado: (2003)

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)

Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15
por: Uchiyama‐Kokubu, Noriko, et al.
Publicado: (2001)

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
por: de Wit, R., et al.
Publicado: (1998)

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
por: Goey, S. H., et al.
Publicado: (1995)

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
por: Bajetta, E., et al.
Publicado: (1998)

Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line.
por: Nooter, K., et al.
Publicado: (1995)

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
por: Klijn, J. G., et al.
Publicado: (1990)

Multidrug Resistance‐associated Protein‐mediated Multidrug Resistance Modulated by Cyclosporin A in a Human Bladder Cancer Cell Line
por: Kim, Wun‐Jae, et al.
Publicado: (1995)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
por: Liu, Kun, et al.
Publicado: (2021)

Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.
por: Broxterman, H. J., et al.
Publicado: (1990)

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
por: Toffoli, G., et al.
Publicado: (1997)

Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro.
por: Twentyman, P. R., et al.
Publicado: (1992)

Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient with Pemphigus Vulgaris
por: Park, So Eun, et al.
Publicado: (2015)

Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
por: Lehne, G., et al.
Publicado: (1998)

Reversal of multidrug resistance by surfactants.
por: Woodcock, D. M., et al.
Publicado: (1992)

Is Cyclosporine Ototoxic?
por: Waissbluth, Sofia
Publicado: (2020)

Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives.
por: GavÃ©riaux, C., et al.
Publicado: (1989)

Synergistic Effect of Cyclosporin A and Verapamil in Overcoming Vincristine Resistance of Multidrug‐resistant Cultured Human Leukemia Cells
por: Ishida, Yasushi, et al.
Publicado: (1990)

Zhi Zhen Fang formula reverses Hedgehog pathway mediated multidrug resistance in colorectal cancer
por: Sui, Hua, et al.
Publicado: (2017)

Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
por: Cascinu, S., et al.
Publicado: (1998)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds
por: TANI, Akiyoshi, et al.
Publicado: (2020)

Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion
por: Zanotti, Ilaria, et al.
Publicado: (2013)

Knockdown of long non-coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells
por: Fan, Heng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9385dmip2hjtnpmp0t25j8i56c